Cancer Research

Can Cellular Therapy Revolutionize Solid Tumor Treatments?
Research & Development Can Cellular Therapy Revolutionize Solid Tumor Treatments?

The notable progress and potential future of cellular therapy for solid tumors seen throughout 2024 signify a transformational year in oncology. The general sentiment within the oncology community is optimistic, particularly with the U.S. Food and Drug Administration's approval of the first

Revolutionizing Multiple Myeloma Treatment: The Power of CAR T-Cell Therapy
Research & Development Revolutionizing Multiple Myeloma Treatment: The Power of CAR T-Cell Therapy

When thinking about the remarkable advancements in multiple myeloma treatment, CAR T-cell therapy generates immense excitement due to its potential to provide deep and enduring responses for patients. Dr. Nina Shah, Global Head of Multiple Myeloma Clinical Development and Strategy at AstraZeneca,

Revolutionary Technology Transforms Colon Cancer Cells to Normal State
Research & Development Revolutionary Technology Transforms Colon Cancer Cells to Normal State

In an unprecedented advancement in cancer treatment, a research team led by Professor Kwang-Hyun Cho from KAIST has developed a groundbreaking technology that targets colon cancer by transforming malignant cells into normal-like cells without killing them. Unlike traditional cancer therapies that

Is Gozetotide Plus Lutetium-177 Therapy a Breakthrough in Prostate Cancer?
Research & Development Is Gozetotide Plus Lutetium-177 Therapy a Breakthrough in Prostate Cancer?

The field of prostate cancer treatment has seen significant advances with the introduction of novel therapies aimed at enhancing patient outcomes. One such promising advancement is the use of gozetotide for the accurate detection of PSMA-positive prostate cancer. This breakthrough is particularly

Can CAR T-Cell Therapy Revolutionize Multiple Myeloma Treatment?
Research & Development Can CAR T-Cell Therapy Revolutionize Multiple Myeloma Treatment?

Multiple myeloma (MM), a complex form of blood cancer originating in plasma cells, relentlessly impairs blood counts and immune functions. Despite breakthroughs in treatment modalities, MM largely remains incurable, with patients often enduring cycles of remission interrupted by relapses. This

AI and ICR Collaborate to Repurpose Drugs for Childhood Brain Cancer
Research & Development AI and ICR Collaborate to Repurpose Drugs for Childhood Brain Cancer

The Institute of Cancer Research (ICR) in London is teaming up with Healx, a biotech firm known for its expertise in artificial intelligence (AI) and machine learning, to develop potential new therapies for diffuse intrinsic pontine glioma (DIPG), a rare and currently untreatable form of childhood

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later